

## DAFTAR PUSTAKA

1. Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal Cancer: Epidemiology, Risk Factors, and Prevention. *Cancers* (Basel). 2024;16(8):1530.
2. Macrae FA. Epidemiology and risk factors for colorectal cancer. UpToDate. Published July 16, 2024. Accessed July 20, 2024. Available from: <https://www.uptodate.com/contents/epidemiology-and-risk-factors-for-colorectal-cancer>
3. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2024. Available from: <https://gco.iarc.who.int/today>
4. Minhajat R, Benyamin AF, Miskad UA. The Relationship Between Histopathological Grading and Metastasis in Colorectal Carcinoma Patients. *Nusantara Medical Science Journal*. 2021:51-60.
5. Macrae FA, Parikh AM, Ricciardi R. Clinical presentation, diagnosis, and staging of colorectal cancer. UpToDate. Published May 19, 2023. Accessed July 19, 2024. Available from: <https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-colorectal-cancer>
6. O'Sullivan DE, Sutherland RL, Town S, et al. Risk Factors for Early-Onset Colorectal Cancer: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2022;20(6):1229-1240.e5.
7. Compton CC. Pathology and prognostic determinants of colorectal cancer. UpToDate. Published June 27, 2024. Accessed July 19, 2024. Available from: <https://www.uptodate.com/contents/pathology-and-prognostic-determinants-of-colorectal-cancer>
8. Stintzing S, Tejpar S, Gibbs P, et al. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. *Eur J Cancer*. 2017;84:69-80.
9. Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials [published correction appears in *JAMA Oncol*. 2017 Dec 1;3(12):1742. doi:10.1001/jamaoncol.2017.4136.]. *JAMA Oncol*. 2017;3(2):194-201. doi:10.1001/jamaoncol.2016.3797
10. Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A

- Systematic Review and Meta-analysis. *JAMA Oncol.* 2017;3(2):211-219.
11. Warschkow R, Sulz MC, Marti L, et al. Better survival in right-sided versus left-sided stage I - III colon cancer patients. *BMC Cancer.* 2016;16:554.
  12. Amado RG, Wolf M, Peeters M, et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. *J Clin Oncol.* 2023;41(18):3278-3286.
  13. Frucht H, Lucas AL. Molecular genetics of colorectal cancer. UpToDate. Published December 8, 2023. Accessed July 19, 2024. Available from: <https://www.uptodate.com/contents/molecular-genetics-of-colorectal-cancer>
  14. Alkader MS, Altaha RZ, Badwan SA, et al. Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan. *Cureus.* 2023;15(1).
  15. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. *Eur J Cancer.* 2009;45(10):1890-1896.
  16. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy [published correction appears in *J Natl Cancer Inst.* 2011 Nov 2;103(21):1639. Kim, George P [added]]. *J Natl Cancer Inst.* 2011;103(11):863-875.
  17. De Renzi G, Gaballo G, Gazzaniga P, et al. Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights. *Oncology.* 2021;99(3):135-143.
  18. Benson AB, Venook AP, Adam M, et al. Colon Cancer, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. Published March 31, 2025. Accessed April 20, 2025. Available from: <https://www.nccn.org>
  19. Brenner DR, Heer E, Sutherland RL, et al. National Trends in Colorectal Cancer Incidence Among Older and Younger Adults in Canada. *JAMA Netw Open.* 2019;2(7).
  20. Macrae FA. Colorectal cancer: Epidemiology, risk factors, and protective factors. UpToDate. Published March 09, 2023. Accessed December 05, 2023. [https://medicowise.com/wp-content/uploads/2023/10/Colorectal-cancer\\_-Epidemiology-risk-factors-and-protective-factors-UpToDate.pdf](https://medicowise.com/wp-content/uploads/2023/10/Colorectal-cancer_-Epidemiology-risk-factors-and-protective-factors-UpToDate.pdf)

21. Labeda I, Lusikooy RE, Mappincara, et al. Colorectal cancer survival rates in Makassar, Eastern Indonesia: A retrospective Cohort Study. *Ann Med Surg (Lond)*. 2021;74:103211. Published 2021 Dec 30.
22. Cai S, Li Y, Ding Y, et al. Alcohol drinking and the risk of colorectal cancer death: a meta-analysis. *Eur J Cancer Prev*. 2014;23(6):532-539.
23. Zhou X, Wang L, Xiao J, et al. Alcohol consumption, DNA methylation and colorectal cancer risk: Results from pooled cohort studies and Mendelian randomization analysis. *Int J Cancer*. 2022;151(1):83-94.
24. Morrison DS, Parr CL, Lam TH, et al. Behavioural and metabolic risk factors for mortality from colon and rectum cancer: analysis of data from the Asia-Pacific Cohort Studies Collaboration. *Asian Pac J Cancer Prev*. 2013;14(2):1083-1087.
25. Minhajat R, Harjianti T, Rasyid H, et al. Colorectal cancer patients' outcome in correlation with dietary and nutritional status: a systematic review. *Ann Med*. 2023;55(2):2281662.
26. La Vecchia S, Sebastián C. Metabolic pathways regulating colorectal cancer initiation and progression. *Semin Cell Dev Biol*. 2020;98:63-70.
27. Malki A, ElRuz RA, Gupta I, et al. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. *Int J Mol Sci*. 2020;22(1):130
28. Kumari S, Sharma S, Advani D, et al. Unboxing the molecular modalities of mutagens in cancer. *Environ Sci Pollut Res Int*. 2022;29(41):62111-62159.
29. Morgado-Diaz JA, editor. *Gastrointestinal Cancers*. Brisbane (AU): Exon Publications; 2022 Sep 30. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK586002/>
30. Li FY, Lai MD. Colorectal cancer, one entity or three. *J Zhejiang Univ Sci B*. 2009;10(3):219-229.
31. Baran B, Mert Ozupek N, Yerli Tetik N, et al. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. *Gastroenterology Res*. 2018;11(4):264-273.
32. Signorelli C, Chilelli MG, Sperduti I, et al. Correlation of Tumor Location to Clinical Outcomes in Colorectal Cancer: A Single-institution Retrospective Analysis. *Anticancer Res*. 2019;39(9):4917-4924.

33. Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, et al. Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. *Gut*. 2008;57(11):1545-1553.
34. Somartini J, Parewangi AL, Daud NA, et al. Profile of CEA Levels in Colorectal Carcinoma patients: A Descriptive Analytic with Cross-Sectional Design. *Int J Med Rev Case Rep*. 2019; 3(1): 5-9.
35. National Health Commission Of The People's Republic Of China. National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version). *Chin J Cancer Res*. 2020;32(4):415-445.
36. Gmeiner WH. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. *Cancers*. 2024; 16(5):1029.
37. Pathak PS, Chan G, Deming DA, et al. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation. *Am Soc Clin Oncol Educ Book*. 2024;44(3).
38. Kumar A, Gautam V, Sandhu A, et al. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. *World J Gastrointest Surg*. 2023;15(4):495-519.
39. Yin J, Cohen R, Jin Z, et al. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. *J Natl Cancer Inst*. 2021;113(12):1705-1713.
40. Phipps AI, Buchanan DD, Makar KW, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. *Br J Cancer*. 2013;108(8):1757-1764.
41. Dinu D, Dobre M, Panaitescu E, et al. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. *J Med Life*. 2014;7(4):581-587.
42. Kim ST, Park KH, Kim JS, et al. Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. *Cancer Res Treat*. 2013;45(1):55-62.
43. Tougeron D, Sueur B, Zaanani A, et al. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. *Int J Cancer*. 2020;147(1):285-296.
44. Yao YC, Jin Y, Lei XF, et al. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. *J Cancer*. 2022;13(9):2912-2921.

45. von Einem JC, Heinemann V, von Weikersthal LF, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. *J Cancer Res Clin Oncol*. 2014;140(9):1607-1614.
46. Heriyanto DS, Yoshuantari N, Akbariani G, et al. High Probability of Lynch Syndrome Among Colorectal Cancer Patients Is Associated With Higher Occurrence of KRAS and PIK3CA Mutations. *World J Oncol*. 2024;15(4):612-624.
47. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. *Br J Cancer*. 2009;100(2):266-273.
48. Rudiman R, Alfariy AN, Lukman K, et al. Associations of KRAS Mutations and Clinical Characteristics of Colorectal Cancer Patients in Indonesia. *Asian Pac J Cancer Prev*. 2024;25(10):3457-3461.
49. Sunagua Aruquipa M, D'Alpino Peixoto R, Jacome A, et al. Association of KRAS G12C Status with Age at Onset of Metastatic Colorectal Cancer. *Curr Issues Mol Biol*. 2024;46(2):1374-1382.